Page last updated: 2024-11-10

tocotrienol, beta

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-tocotrienol : A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 5 and 8 and a farnesyl chain at position 2. It has been isolated from various cultivars of wheat. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5282348
CHEBI ID33275
SCHEMBL ID66599
SCHEMBL ID16430159
MeSH IDM0218843

Synonyms (49)

Synonym
BIDD:PXR0058
.epsilon.-tocopherol
(2r)-3,4-dihydro-2,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-2h-1-benzopyran-6-ol
CHEBI:33275
(2r)-2,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2h-chromen-6-ol
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-, (2r)-
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-, (2r)- (9ci)
3,4-dihydro-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-2h-1-benzopyran-6-ol
epsilon-tocopherol
beta-tocotrienol
d-beta-tocotrienol
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-, [r-(e,e)]-
490-23-3
6-chromanol,2,5,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)- (8ci)
tocotrienol, beta
2r,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2h-chromen-6-ol
LMPR02020055
(2r)-2,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
einecs 207-708-0
chh810zm8c ,
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2-((3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrien-1-yl)-, (2r)-
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2-((3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl)-, (2r)-
unii-chh810zm8c
[r-(e,e)]-3,4-dihydro-2,5,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2- ((3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrien-1-yl)-, (2r)-
.beta.-tocotrienol
j37.066e ,
d-.beta.-tocotrienol
.epsilon.-tokoferol
beta-tocotrienol [who-dd]
.beta.-tocotrienol [mi]
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2- ((3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl)-, (2r)-
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-, (r-(e,e))-
SCHEMBL66599
tocotrienol, 5,8-dimethyl
a-tocotrienol
SCHEMBL16430159
beta-tocotrienol, analytical standard
Q171542
2,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
A934798
(2r)-2,5,8-trimethyl-2-[(3e,7e)-4,8,12-trimethyl-3,7,11-tridecatr ien-1-yl]-6-chromanol
MS-27089
DTXSID50883401
HY-108693
CS-0029986
d-beta- tocotrienol
beta -tocotrienol
AKOS040744870

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The tocotrienol-rich fraction (TRF) of palm oil inhibited growth of MCF7 cells in both the presence and absence of estradiol with a nonlinear dose-response but such that complete suppression of growth was achieved at 8 microg/mL."( Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.
Darbre, P; Dils, R; Nesaretnam, K; Stephen, R, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tocotrienolA tocol in which the hydrocarbon chain at position 2 contains three double bonds.
vitamin EAny member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
vitamin E biosynthesis (tocotrienols)113

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.56)18.7374
1990's5 (27.78)18.2507
2000's4 (22.22)29.6817
2010's6 (33.33)24.3611
2020's2 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]